Q3 2021 13F Holders as of 30 Sep 2021
-
Type / Class
-
Equity / Class A Common Stock, $0.0001 par value per share
-
Shares outstanding
-
99.8M
-
Number of holders
-
14
-
Total 13F shares, excl. options
-
1.1M
-
Shares change
-
+1.1M
-
Total reported value, excl. options
-
$19.6M
-
Value change
-
+$19.6M
-
Number of buys
-
14
-
Price
-
$17.82
Significant Holders of Rani Therapeutics Holdings, Inc. - Class A Common Stock, $0.0001 par value per share (RANI) as of Q3 2021
14 filings reported holding RANI - Rani Therapeutics Holdings, Inc. - Class A Common Stock, $0.0001 par value per share as of Q3 2021.
Rani Therapeutics Holdings, Inc. - Class A Common Stock, $0.0001 par value per share (RANI) has 14 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 1.1M shares
of 99.8M outstanding shares and own 1.1% of the company stock.
Largest 10 shareholders include Nan Fung Group Holdings Ltd (494K shares), VANGUARD GROUP INC (283K shares), CAAS CAPITAL MANAGEMENT LP (75K shares), GOLDMAN SACHS GROUP INC (60.6K shares), Squarepoint Ops LLC (50K shares), STIFEL FINANCIAL CORP (38K shares), MILLENNIUM MANAGEMENT LLC (29K shares), GEODE CAPITAL MANAGEMENT, LLC (21.6K shares), STATE STREET CORP (19.7K shares), and NORTHERN TRUST CORP (11.4K shares).
This table shows the top 14 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.